SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously disclosed on a current report on Form 8-K, Sunesis Pharmaceuticals, Inc. (the “Company”) appointed Dayton Misfeldt as its interim Chief Executive Officer, effective January1, 2018, and, as consideration for his services in such interim role through June30, 2018, Mr.Misfeldt was granted an option to purchase 200,000 shares of the Company’s common stock to its 2011 Equity Incentive Plan (the “Plan”), to vest in six equal monthly installments measured from January1, 2018. Since the Company expects Mr.Misfeldt to continue in the interim Chief Executive Officer role as the Company continues its search for a permanent Chief Executive Officer and, as compensation for his continued service in this role, on June20, 2018, the Company granted Mr.Misfeldt an additional option to purchase 200,000 shares of the Company’s Common Stock, to the Plan, with an effective grant date of June29, 2018, (the last business day of the month, in accordance with the Company’s practice), to vest monthly over six equal monthly installments measured from the grant date. All rights and obligations with respect to Mr.Misfeldt’s new grant will be as set forth in the Plan and applicable Plan documents.
About SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS)
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.